Neurotrophin Signaling Dysfunction Hypothesis in Parkinson's Disease: The progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta results from impaired neurotrophin signaling, including reduced BDNF, GDNF, and NGF activity, leading to loss of trophic support and vulnerability to pathological insults["@kalia2021"].
PD Cure Roadmap Gap #1 (40 pts): Can neurotrophin signaling be restored to prevent dopaminergic neuron loss?
The neurotrophin family comprises a group of structurally related proteins critical for neuronal survival, development, and function. Key members include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and neurotrophin-3 (NT-3). Each neurotrophin binds to specific receptor tyrosine kinases (Trks) with high affinity: NGF to TrkA, BDNF and NT-4/5 to TrkB, and GDNF to the GFRα1/Ret receptor complex[@allen2013].
These trophic factors are essential for the development and maintenance of the nigrostriatal pathway. During development, dopaminergic neurons in the substantia nigra depend on target-derived neurotrophins for survival and proper innervation. GDNF was originally identified as a potent survival factor for dopaminergic neurons and remains one of the most potent neurotrophic molecules for these cells[@gomez2019].
BDNF is expressed in both the substantia nigra and striatum, where it supports the survival and function of dopaminergic neurons. The TrkB receptor is expressed on dopaminergic neurons in the SNc, and BDNF signaling through TrkB activates multiple pro-survival pathways including PI3K/Akt, MAPK/ERK, and PLCγ. These pathways promote neuronal survival, regulate synaptic plasticity, and support mitochondrial function[@hyman1991].
GDNF signals through a distinct mechanism, binding to GFRα1 on the cell surface and activating the Ret tyrosine kinase. GDNF is produced in the striatum and retrogradely transported to dopaminergic cell bodies, where it activates survival pathways similar to those triggered by BDNF. The GDNF family includes neurturin (NRTN), artemin (ARTN), and persephin (PSPN), which signal through related GFRα receptors[@chohan2011].
Multiple lines of evidence suggest that neurotrophin signaling is impaired in Parkinson's disease:
Reduced BDNF Expression: Post-mortem studies have consistently demonstrated reduced BDNF levels in the substantia nigra and striatum of PD patients[@howells2000]. This reduction correlates with disease severity and may contribute to the progressive loss of dopaminergic neurons. The BDNF Val66Met polymorphism, which affects BDNF secretion, has been associated with increased PD risk in some populations.
Altered GDNF Signaling: While GDNF levels in the striatum may be preserved in PD, the retrogradely transported GDNF signal to dopaminergic cell bodies may be disrupted. This could result from axonal transport deficits, which are an early feature of PD pathology. Some studies have also reported reduced GFRα1 expression in PD substantia nigra[@garlid2014].
Trk Receptor Signaling: Activation of Trk receptors triggers downstream signaling cascades that promote neuronal survival. In PD, there is evidence of impaired TrkB signaling, which could reduce the neuroprotective effects of BDNF. This may involve alterations in receptor expression, phosphorylation, or downstream signaling molecules[@rose2003].
The delivery of neurotrophins from striatal terminals to nigral cell bodies depends on efficient retrograde axonal transport. Several features of PD pathology may impair this transport:
| Cohort | N | Description |
|--------|---|-------------|
| Early PD | 60 | Hoehn-Yahr 1-2, disease duration <2 years |
| Advanced PD | 60 | Hoehn-Yahr 3-4 |
| Healthy Controls | 40 | Age-matched |
| LRRK2 carriers | 30 | Asymptomatic and PD |
Goal: Characterize neurotrophin signaling status in PD vs. controls
Methods:
Goal: Validate retrograde transport defect
Methods:
Goal: Test novel AAV-GDNF delivery
Design: Open-label, dose-escalation
| Dose | N | Delivery |
|------|---|----------|
| Low | 10 | Bilateral putamen |
| Medium | 10 | Bilateral putamen + SN |
| High | 10 | Bilateral putamen + SN |
Endpoints:
| Biomarker | Matrix | Method | Reference |
|-----------|--------|--------|-----------|
| BDNF | CSF | ELISA | Abbott |
| GDNF | CSF | ELISA | R&D Systems |
| p-TrkA | PBMC | Western | Cell Signaling |
| p-TrkB | CSF | Simoa | Quanterix |
AAV-mediated delivery of GDNF to the striatum has shown remarkable efficacy in preclinical PD models. By engineering neurons to produce GDNF locally, continuous trophic support can be provided without the need for repeated protein delivery. Several clinical trials have tested this approach with varying results[@somayajulu2022].
Challenges:
Alternative approaches include developing small molecules that can cross the blood-brain barrier and activate Trk receptors. These include:
Given the multifactorial nature of neurotrophin dysfunction in PD, combination approaches may prove most effective:
| Risk | Mitigation |
|------|------------|
| AAV immunogenicity | Pre-screening for neutralizing antibodies |
| Off-target effects | Targeted putamen delivery |
| Disease progression | Early-stage enrollment |
| Phase | Cost |
|-------|------|
| Phase 1 | $500K |
| Phase 2 | $800K |
| Phase 3 | $2.5M |
| Total | $3.8M |